Try our beta test site

Smoking Study With Behavioral Therapy for Hypertensive Patients (VANQUISH)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by UConn Health.
Recruitment status was:  Active, not recruiting
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
William B. White, University of Connecticut Health Center Identifier:
First received: March 24, 2009
Last updated: December 9, 2013
Last verified: December 2013

March 24, 2009
December 9, 2013
April 2009
July 2014   (Final data collection date for primary outcome measure)
Short-term and long-term smoking abstinence and improved health benefits [ Time Frame: Weeks 5,6,8,12,24,36,52 ]
Same as current
Complete list of historical versions of study NCT00879177 on Archive Site
Decrease in blood pressure and heart rate in hypertensive subjects [ Time Frame: Week 6 and Week 24 ]
Same as current
Not Provided
Not Provided
Smoking Study With Behavioral Therapy for Hypertensive Patients
Contingency Management for Initiating Smoking Abstinence in Patients With Hypertension
In total, 260 patients with pre- and stage I hypertension, who are regular smokers, will be randomized to: varenicline alone or varenicline plus behavioral therapy. Patients in both conditions will receive varenicline (titrated to a maximal dose of 1.0 mg twice daily) for 12 weeks along with standard smoking cessation therapy and regular carbon monoxide (CO) and cotinine monitoring. A significantly higher proportion of behavioral therapy patients are expected to achieve and maintain long durations of abstinence than patients receiving varenicline alone. Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be primary clinical outcomes. The investigators expect that BP and HR will decrease more among behavioral therapy than non-behavioral therapy patients and reductions in smoking may mediate decreases in these indices.
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Cigarette Smoking
  • Hypertension
  • Drug: Varenicline
    Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
    Other Name: CHANTIX
  • Behavioral: behavioral therapy
    confirmed negative smoking status at different time points
  • Active Comparator: Group A
    Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
    Intervention: Drug: Varenicline
  • Experimental: Group B
    Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
    • Drug: Varenicline
    • Behavioral: behavioral therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
July 2014
July 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • regular smokers, with no period of abstinence exceeding 3 months in past year
  • expired CO of at least 8 ppm
  • self-reported desire to stop smoking
  • at least 18 years of age
  • resting systolic BP of 120-160 mmHg and/or diastolic BP of 80-100 mmHg but otherwise in good health (see exclusion criteria)
  • if on antihypertensive medication, have not changed medications during the previous month and do not intend to change in the next 3 months
  • English speaking

Exclusion Criteria:

  • receipt of smoking cessation treatment (behavioral or pharmacological) in the past month
  • serious or unstable medical disease within the past 6 months, including myocardial infarction, cancer, congestive heart failure, kidney failure, stroke, or seizures
  • evidence or history of allergic reactions contraindicating varenicline use or clinically significant laboratory or electrocardiographic (ECG) abnormalities
  • breastfeeding, pregnant or not using effective contraception if a woman of childbearing potential
  • arm circumference of >42 cm, which precludes accurate BP monitoring
  • serious psychiatric illness in past 6 months (e.g., schizophrenia, psychosis, suicide risk, drug or alcohol dependence other than nicotine)
  • use of tobacco containing products other than cigarettes in past month and do not agree to abstain from use of these products during study participation
  • ongoing use of any of the following medications: nicotine replacement therapies, monoamine oxidase inhibitors, antipsychotics, mood stabilizers, or naltrexone
  • in recovery for pathological gambling
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
08-218, R01DA024667
Not Provided
Not Provided
Not Provided
William B. White, University of Connecticut Health Center
UConn Health
National Institute on Drug Abuse (NIDA)
Principal Investigator: William B White, M.D. UConn Health
UConn Health
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP